Context: Mineralocorticoid (MC) replacement therapy in patients with primary adrenal insufficiency (PAI) was introduced more than 60 years ago. Still, there are limited data on how MC substitution should be optimized, because MC dosing regimens have only been systematically investigated in a few studies. We review the management of current standard MC replacement therapy in PAI and its plausible impact on outcome.
Results:
The current standard treatment consists of fludrocortisone (FC) given once daily in the morning, aiming at normotension, normokalemia, and plasma renin activity in the upper normal range. Available data suggest that patients with PAI may be underreplaced with FC as symptoms and signs indicating chronic MC underreplacement, such as salt craving and postural dizziness persist, in many treated patients with PAI. Data acquired from large registry-based studies show that glucocorticoid doses for replacement in PAI are higher than those estimated from endogenous production. Glucocorticoid overreplacement may reduce the need of MC replacement but may also be a consequence of inadequate MC replacement.
Conclusions:
The commonly used MC replacement in PAI may not be adequate in some patients. Insufficient MC substitution may be responsible for poor cardiometabolic outcome and the failure to restore well-being adequately in patients with PAI. Well-designed studies oriented at optimizing MC replacement therapy are urgently needed. (J Clin Endocrinol Metab 103: 376-387, 2018) P rimary adrenal insufficiency (PAI) is a rare disease, characterized by insufficient secretion of glucocorticoids (GCs), mineralocorticoids (MCs), and androgens (1) . The most common cause of PAI in industrialized countries is autoimmune adrenalitis, which is associated with detection of circulating 21-hydroxylase autoantibodies (1, 2) . Measurement of these autoantibodies is therefore of value to determine the etiology of PAI (3, 4) .
Autoimmune PAI may occur either as an isolated entity (40% of all cases) or as part of an autoimmune polyendocrine syndrome (60%) (1) . Other etiologies to mention are infectious, genetic, metastatic, hemorrhagic, and infiltrative disorders, surgery, and drugs (3) (4) (5) . Longchain fatty acids should be investigated to assess adrenoleukodystrophy in men with PAI without detectable antibodies (6) .
If untreated, PAI can be lethal. Before the availability of GCs, the majority of patients died within 2 years of diagnosis (5, 7) . Treatment of PAI consists of lifelong replacement therapy with GCs and MCs, whereas androgen replacement is less frequent and mainly considered in women. MC substitution is needed in PAI to correct hypovolemia, hyperkalemia, hyponatremia, and hypotension (3) . Secondary adrenal insufficiency (SAI) is a different disease entity caused by a pituitary disorder disrupting adrenocorticotropic secretion that leads to GC deficiency. Patients with SAI do not need MC replacement because the secretion of aldosterone is mostly stimulated by the renin-angiotensin-aldosterone system (RAAS), with only a minor component under the control of adrenocorticotropic hormone (ACTH) (3, 8) .
Here, we present a review on MC replacement in PAI, including the outcomes associated with current therapy, to promote further discussions on the safety and effectiveness of conventional treatment. We searched Medline for articles published in English until 21 May 2017, with the following keywords: adrenal insufficiency, MC deficiency, aldosterone, cardiovascular disease, hypertension, and heart failure (HF). Studies including a detailed analysis of MC dosing regimens and monitoring were identified and summarized in Table 1 . This review focuses on MC replacement in adult patients with autoimmune adrenalitis.
Aldosterone Secretion and Regulation
Aldosterone was discovered in the adrenal gland more than 60 years ago (17) . Subsequently, it was recognized as a potent stimulus for sodium reabsorption, acting on the distal segment of the convoluted tubule in the kidney. Aldosterone mediates its effects by the MC receptor (MR), a member of the nuclear receptor superfamily widely expressed in tissues not only involved with salt balance, including kidney, brain, lung, colon, and salivary and sweat glands (18) .
Aldosterone secretion is mainly regulated by the RAAS and the potassium ion, whereas ACTH and other proopiomelanocortin peptides are minor modulators (8, 19) (Fig. 1) . Therefore, aldosterone secretion is not impaired in SAI (4, 19) . The MR, upon binding with aldosterone, is transferred to the cell nucleus where the ligand-receptor complex interacts with hormone-responsive elements, modulating transcription (8, 18) .
Aldosterone, however, mediates its actions not only via the "classic" transcriptional mechanisms but also through "rapid" (,15-minute) mechanisms, described as nongenomic signaling of MC (20) . Therefore, these effects seem to be independent of MRs and are mediated by G protein-coupled estrogen receptors (GPERs) (20, 21) .
GPER expression is ubiquitous; in vascular cells, it is present in both endothelial and smooth muscle cells. Activation of GPER mediates rapid endothelium-dependent vasodilation, whereas MR activation produces vasoconstriction. Thus, the effect of aldosterone on endothelial function can vary depending on the balance between MR and GPER expression (20, 21) .
Aldosterone, like angiotensin II, has other endocrine activities essential for circulatory homeostasis. They contribute to blood coagulation (22) and vasoconstriction to preserve arterial pressure in case of hypovolemia and stimulate thirst. They are also involved in regulating inflammatory and reparative processes that follow tissue injury (19, 22, 23) (Fig. 1) .
MC Activity of GCs
MRs and GC receptors have analogous DNA-binding domains (94% homology for amino acids) and similar ligand-binding domains (57%) (8) . Cortisol has high affinity for the MR allowing for MC activity. However, a local enzyme, 11b-hydroxysteroid-dehydrogenase type 2 (11b-HSD2), which is colocalized with the MR, converts active cortisol to inactive cortisone, protecting MRs from its effects (8) .
Fludrocortisone (FC), a synthetic MC used in PAI for replacement treatment, has a fluorine atom attached to the carbon 9 position that protects the molecule from rapid conversion by 11b-HSD2. FC exhibits 10-fold higher MC potency than aldosterone (24, 25) . Different GCs have different MC activity (26) . Published comparative data on MC potency of steroids are scanty. Hydrocortisone (HC), the most frequently used short-acting GC in PAI, exhibits the highest MC potency (24) . Oelkers et al. (11) defined the MC potency of 1 mg FC as 1 MC unit (MCU). Because the MC potency of HC is about 1/400th that of FC, 0.4 mg HC may be regarded as 1 MCU (11). Therefore, 15 to 25 mg of HC, the current recommended daily dose in PAI (9), corresponds to approximately 0.04 to 0.06 mg of FC (11, 24) .
A study that investigated the effect of higher vs lower GC replacement dose (30 to 40 vs 15 to 20 mg HC/d) on the RAAS and blood pressure (BP) in patients with SAI showed an increase in BP and a decrease in renin, aldosterone, and potassium levels in the group on the higher dose (27) . These findings are consistent with activation of the MR by HC, suggesting that MC substitution may be superfluous in patients using higher doses of HC (30 to 40 mg/d). By contrast, patients treated with synthetic GCs require higher FC doses as prednisolone exhibits fourfold lower MC activity than HC and dexamethasone does not exert any MC activity (26). (4) PRA correlated better with MC dose than plasma potassium and sodium levels. Adrenoleukodystrophy (2) PRA was titrated to the upper normal range between 3 and 10 ng/mL/h (0.288-11.01 ng/ mL/h) to achieve the optimal individual MC dose. Other adrenal disorders (2) Conversely, FC exhibits GC activity, binding to the GC receptor with high affinity. In vitro studies reported that FC exhibited a 10-fold higher GC potency than that of cortisol (26) . Recent clinical trials seem to support this hypothesis, showing that FC exerts an inhibitory effect on the hypothalamic-pituitary-adrenal (HPA) axis. Administration of 0.5 mg of FC in healthy subjects inhibited nocturnal HPA axis activity by reducing nighttime cortisol and ACTH levels (28) . Administration of FC in doses between 0.075 and 0.3 mg inhibited the HPA response to corticotrophin-releasing hormone (29) . Conversely, 0.05 mg of FC did not modify the corticotrophinreleasing hormone-stimulatory effect on both ACTH and cortisol, suggesting that FC exerts inhibitory action on the HPA axis in a dose-dependent manner (29) . However, in a study including patients with PAI, 0.1 mg of FC did not show any inhibitory effect on ACTH secretion (30). 
Clinical and Biochemical Features of MC Deficiency in PAI
Common clinical features of PAI are usually nonspecific, including weakness, anorexia, depression, anxiety, and weight loss (31) . Patients may have episodes of vomiting, abdominal pain, and diarrhea, often leading to false diagnosis of gastrointestinal or psychiatric disease (32) . Hyperpigmentation of the skin and mucous membranes is a more specific sign due to increased ACTH secretion and melanocortin levels, which is synthesized with ACTH from pre-pro-opiomelanocortin (3). Orthostatic hypotension, salt craving, and hyperkalemia are more specifically related to the MC deficiency (Table 2 ) (10) . A Norwegian population-based observational study reported that hyperpigmentation was present in 74% of the patients, hypotension in 64%, and salt craving in 68% at onset (Table 2 ) (10) . The frequency of all symptoms was markedly reduced after replacement therapy (10) . However, 24% of treated patients still reported salt craving and 15% postural dizziness, suggesting that the MC replacement may have been inadequate. Because patients do not report salt craving unless specifically asked about it, this symptom is probably underestimated in medical textbooks, which report frequencies of 12% to 19% (4, 10) .
Aldosterone deficiency leads to hyponatremia, hypovolemia, and hypotension, with associated hyperkalemia and acidosis. Hypovolemia is a strong stimulus for arginine vasopressin secretion that leads to worsened hyponatremia. Furthermore, arginine vasopressin secretion may be further increased by GC deficiency (33) . Although hyponatremia may also be detected in SAI, hypovolemia, hyperkalemia, and metabolic acidosis are only observed in PAI, specifically reflecting MC deficiency (33) .
Adrenal failure seems to progress through four stages of functional impairment with stage 1 being characterized by elevated plasma renin activity (PRA) and inappropriately normal or low aldosterone levels (34) . In stage 2, a low cortisol response after stimulation is detected. Increased ACTH and low basal cortisol are distinctive signs in stages 3 and 4, respectively (34) . Aldosterone levels and PRA should be assessed in all patients with clinical suspicion of PAI, because MC deficiency may be the only sign of adrenal failure in the early stage. In reviewing MC replacement in PAI, we acknowledge that, in some cases, MC secretion may not be impaired.
Both PRA/active renin and aldosterone measurements have several laboratory challenges with a lack of internationally accepted standard reference range; therefore interpretation depends on local reference interval provided by the laboratory report (3) . A few studies have suggested to assess aldosterone response to ACTH stimulation test (11); however, current guidelines only recommend basal Figure 1 . Diagrammatic representation of aldosterone secretion and systemic aldosterone actions. Aldosterone secretion is mainly regulated by the RAAS and the potassium ion. Aldosterone induces Na + and water reabsorption in exchange for K + in the distal tubule and collecting duct of the nephron. Aldosterone is also involved in regulating cardiac remodeling, arterial stiffness, and inflammatory process that follows tissue injury. Renal excretion of K + and Na + is regulated by several feedback loops within the RAAS. A "short" feedback loop inhibits renin production when sufficient quantities of angiotensin II are formed, whereas a "long" feedback loop regulates changes in volume and BP. Increases in potassium levels stimulate aldosterone production independently of the RAAS. renin and aldosterone measurement (3, 4) . All patients with confirmed MC deficiency should receive MC replacement therapy, whatever the etiologic cause of damage to the adrenal glands (3). MC deficiency may also occur in isolated hypoaldosteronism due to aldosterone synthase deficiency. Assessment of PRA and aldosterone levels is a valuable tool for diagnosis of this rare congenital disease (8) .
Current Treatment and Outcomes
A synthetic MC, desoxycorticosterone acetate, was identified in 1937 and introduced for treatment in 1939. FC, the currently used MC, was discovered and patented 15 years later (31). Since then, few studies aimed at optimizing MC treatment have been published.
Long-term outcome in PAI on conventional treatment was for a long time considered similar to that of healthy subjects (5, 7). Recent studies, however, have shown that morbidity is high, life expectancy is reduced mainly due to cardiovascular diseases (35, 36) , and quality of life (QoL) is impaired (37, 38) . Whether the poor outcome in PAI is related to nonphysiological GC replacement, inadequate MC substitution, or the underlying conditions per se has not been explained and requires further studies.
Throughout the last two decades, several efforts have been performed to optimize GC treatment (37, 39) , although MC replacement treatment has received little attention. The current standard replacement consists of FC (0.05 to 0.2 mg) given once daily in the morning (3, 39) . It is widely recognized that the majority of patients with PAI use higher-than-recommended doses of GC based on endogenous production (9) . It may be speculated that one of the reasons for GC overreplacement may be due to inadequate MC replacement (12, 40) . Symptoms and signs indicating chronic underreplacement of FC are the persistent salt craving and postural dizziness reported by 24% and 15% of treated patients, respectively (Table 2) (10). In addition, it has been demonstrated that cognitive function and mood in PAI are in part related to MR occupation (41); therefore the low QoL in PAI may also suggest inadequate MC substitution.
MC Dosing Regimens

Current replacement therapy
The synthetic MC, 9a-FC, is used as replacement therapy in PAI, because neither of the two natural MCs, 11-deoxycortisol or aldosterone, is suitable (4). The former was administered as subcutaneous or intramuscular injection in sesame or peanut oil, but is not used anymore (42) . The latter has a rapid hepatic inactivation and a short half-life (25) .
Current replacement therapy consists of 0.05 to 0.2 mg of FC (4) given once daily in the morning, as physiological aldosterone secretion follows a circadian rhythm similar to that of cortisol, with peaks at 8:00 AM and nadirs at 11:00 PM (43) . A Swedish population-based observational study reported that MC replacement was used by 89% of all patients with PAI, with a median FC dose of 0.1 mg/d (range, 0.014 to 1.0 mg/d) (9) . Previous analysis of 664 patients with PAI from Norway had shown that the mean dose of FC was 0.1 mg/d (10) .
The available forms of FC preparation include 0.1-and 0.05-mg tablets that need to be refrigerated according to the new formulation instructions (e.g., for Florinef), even though the decay rate is as low 0.1% over the first 6 months at room temperature (25) .
FC is quickly absorbed and converted to 9a-fluorocortisol, the active molecule. Maximal plasma concentration of FC occurs 90 to 120 minutes after intake and mean plasma half-time is 4.9 hours. Therefore, FC is suitable for once-daily administration. FC is mainly eliminated by urinary excretion (25) .
The starting FC dose consists of 0.05 to 0.1 mg daily (3), which is then titrated in steps of 0.025 to 0.05 mg (3, 4) (Fig. 2) . A higher dose (up to 0.5 mg daily) is needed in newborns and children, because their MC sensitivity is lower compared with adults, as well as in the last trimester of pregnancy, when high levels of progesterone may counteract the effects of MC (4, 25, 44) . Otherwise, dose adjustments are rarely recommended, but this should probably be done more often. Temporary dose increments of 50% to 100% may however be recommended in hot climates and conditions that promote excessive sweating, such as long-lasting exercise (3, 11, 45) . Medications that affect BP and electrolytes, including diuretics, acetazolamide, carbenoxolone, NSAIDS, and drospirenone, might necessitate FC dose adjustments (4). Liquorice potentiates the MC effect of HC and should be avoided. Glycyrrhetinic acid and its metabolite glycyrrhizic acid, present in liquorice, are inhibitors of 11b-HSD2, which plays a crucial role in protecting MRs from GC activation (46) .
Monitoring
Patients with PAI require lifelong steroid therapy, and monitoring is critical to avoid under-or overreplacement. MC replacement should be assessed clinically by measuring BP, inquiring about salt craving, and identifying the presence of peripheral edema, although the latter has low sensitivity (3). However, more objective markers are needed. Some biochemical markers appear useful to guide MC replacement. Sodium, potassium, and PRA/plasma renin concentration (PRC) levels are valuable tools, although data supporting their usefulness are limited. MC replacement should aim at normotension, normokalemia, and PRA/PRC in the upper normal range (4, 11) .
PRC has mostly replaced PRA in clinical practice. It is known that GC may modify plasma angiotensinogen concentration, which may increase PRA. Reid et al. (47) demonstrated that changes in angiotensinogen levels had an influence on PRA but not on PRC in adrenolectomized dogs. Therefore, assessment of PRC may be more reliable than PRA in the management of PAI. However, a formal comparison between PRA and PRC has not been performed.
Published data on the ideal PRA/PRC level in patients with PAI are scanty ( Table 1) . Smith et al. (12) assessed MC substitution in 10 patients with PAI, evaluating electrolytes levels, PRA, and plasma volume (PV). The latter was measured by means of a standard dose of 125 I-labeled albumin with a 10-minute equilibration time. Nine of 10 patients were sodium depleted, with a mean PV 11% below predicted and high levels of PRA despite receiving 0.05 to 0.1 mg/d of FC. There was a decrease in PRA and in potassium and an increase in PV when a daily dose of 0.3 mg of FC was administered. Most patients required 0.2 mg/d to maintain adequate electrolyte balance, PV, and PRA within the normal range (12). Oelkers et al. (11) showed that PRA correlated better with the MC dose than potassium and sodium levels alone if PRA was targeted in the upper normal range (Fig. 3) .
The prolonged administration of MCs produces an escape phenomenon from the salt-retaining effect, and a new steady state is obtained after approximately 1 week (48). Therefore, electrolyte levels and PRA/PRC should be monitored not earlier than 1 or 2 weeks after changing FC dose (12) . The time of the day for blood sampling is not critical, because PRA/PRC levels do not significantly fluctuate throughout the day (13) .
Some studies have raised doubts about MC monitoring by measuring PRA levels. Thompson et al. (14) observed eight Addison patients on constant intake of GC and different doses of FC, evaluating PRA, BP, and potassium levels after 2-week periods on each FC dose. Interestingly, PRA remained normal throughout the study in four patients even after FC withdrawal, suggesting that the MC substitution was unnecessary for the electrolyte balance. FC overtreatment was indicated by low potassium but not by PRA levels, which failed to identify excessive MC substitution (14) ( Table 1) .
Cohen et al. (15) suggested that PRC is of value in determining MC underreplacement, whereas plasma atrial natriuretic peptide (ANP) is a more sensitive index of FC overreplacement. ANP is a marker of sodium and water status. It is secreted in response to an increase in intravascular volume. ANP may be complementary to PRC in the individualization of FC doses. However, both PRC and ANP exhibit high variability, depending on other factors such as sodium intake and renal function. The clinical utility of these measurements should not be overestimated and they should be evaluated together with clinical findings (15) .
High BP, rapid weight gain, and hypokalemia indicate overtreatment. Conversely, weakness, postural hypotension with a postural drop in arterial BP .20 mm Hg, weight loss, dehydration, salt craving, hyperkalemia, and high PRA/PRC levels indicate undertreatment and the need to adjust the FC dose because underreplacement may predispose to adrenal crises (Fig. 2) . In fact, salt depletion and consequent hypovolemia are reported to be strong triggers for adrenal crises (4).
MC Replacement and Cardiovascular Disease
The relative risk of death in PAI is increased and is predominantly related to cardiovascular disease (36) . Supraphysiological doses of GCs increase the prevalence of risk factors for cardiovascular disease (49, 50).
However, bearing in mind the direct cardiovascular effects of MC through its receptor and the nongenomic action through GPER, MC replacement may also have an important role in a compromised outcome among patients with PAI.
Hypertension
Hypertension has been reported in 14% of patients with PAI (9) . There is a lack of evidence to guide management of MC replacement in this condition. Conversely, the pathophysiological role of aldosterone in essential hypertension has been studied extensively. Aldosterone increases BP, exerting its effects on vasculature, brain, heart, and kidneys (19, 51) (Fig. 1) . It enhances sympathetic nervous system activity, reduces vascular compliance and endothelialderived vasorelaxation, and increases extracellular volume. There is considerable experimental evidence that aldosterone increases left ventricular (LV) mass and cardiac output and contributes to the development of nephrosclerosis and renal fibrosis (19, 51) (Fig. 1) . Exogenous administration of MC has induced lesions of malignant hypertension and stroke in a rat model (52) . Conversely, MR antagonists reduce BP and promote beneficial effects on myocardial fibrosis in patients with hypertension (22, 53) .
In accordance with this evidence, reduction or even withdrawal of MC replacement has been suggested in patients with PAI that develop hypertension (16) . However, an inappropriate decrease or cessation of FC dose in euvolemic patients may lead to reduced PV with consequently increased angiotensin II, exerting an important vasoconstrictor effect that may worsen the hypertension (11, 19, 54) (Fig. 1) . Therefore, when a patient with PAI develops hypertension, MC replacement should not be withdrawn, but an attempt to optimize both MC and GC replacement should be performed (3, 54) .
Supraphysiological doses of GCs may lead to hypertension independently of any effect on MRs (55) . Administration of four different synthetic GCs at doses calculated to be similar for GC activity, but which had https://academic.oup.com/jcemlow or no MC potency, to six healthy subjects for 5 days showed a significant BP increase with all steroids (55) . A further study found a significant positive association between the HC equivalent dose and the incidence of hypertension; conversely, no association was found between the FC dose and hypertension (9). Buning et al. (27) determined the effects of a higher vs a lower HC replacement dose (0.2 to 0.3 mg vs 0.4 to 0.6 mg HC/kg body weight) on BP, showing that the higher dose led to significant increase in BP. According to these findings, the GC dose should be optimized as the first therapeutic step in patients with PAI and hypertension. Once GC replacement has been adjusted, assessment of electrolytes and PRA/PRC should be considered to evaluate MC substitution. If signs or symptoms of overtreatment are detected, the FC dose should be reduced (54) . If BP is still high, antihypertensive medications should be considered in line with international guidelines (3, 4, 54) . A formal comparison between the available antihypertensive agents remains unexplored. However, diuretics, especially aldosterone antagonists, such as spironolactone or eplerenone, have potential adverse effects on PV and potassium excretion and should be avoided (54) . Because the majority of antihypertensive treatments affect the RAAS, monitoring of renin levels is less helpful to guide MC substitution when these antihypertensive drugs are being used (54, 56) .
HF
There is considerable experimental and clinical evidence that aldosterone and angiotensin II promote cardiac fibrosis by inducing myofibroblast proliferation and accumulation of collagen (19, (51) (52) (53) (57) (58) (59) (Fig. 1) . High aldosterone levels are associated with an increased mortality rate in cohorts of patients with HF (60) . Prolonged exposure to high aldosterone concentrations have a deleterious effect on cardiovascular tissues, leading to LV hypertrophy, diastolic dysfunction, and cardiovascular events independently of BP (61, 62) . The frequency of cardiovascular events, including nonfatal myocardial infarction and HF is also higher in patients with primary aldosteronism than in properly matched controls with essential hypertension, supporting the detrimental effects of excessive aldosterone exposure (63) .
On the other hand, little is known about cardiovascular abnormalities when adrenal steroids secretion is impaired. Cruz-Topete et al. (64) have evaluated the effects of long-term adrenalectomy on cardiac function in experimental models. Animals were adrenalectomized at 1 month of age and maintained on 0.154 M saline for 3 to 6 months after surgery. The chronic effects of GC and MC deficiency were assessed by transthoracic echocardiography and electrocardiographic analysis. Heart weight and LV mass were significantly elevated in 6-month adrenalectomized mice, whereas LV function was significantly decreased when compared with controls. Moreover, genome-wide microarray analysis was performed on hearts from 6-month adrenalectomized and control mice, showing an aberrant expression of a large number of genes associated with cardiovascular disease 6 months after surgery (64) . Because PAI diagnosis is often delayed, with the half of patients receiving the diagnosis more than 1 year after the onset of symptoms (32), we can theorize that patients with PAI may exhibit an aberrant expression of genes associated to cardiovascular abnormalities that may lead to higher cardiovascular comorbidity and mortality, possibly independently of subsequent replacement therapy.
A small case series has reported a high incidence of HF in PAI, with seven out of 22 patients with PAI developing HF over 30 years of follow-up (65) . The HF was managed with administration of diuretics in three patients, FC reduction in five, and FC withdrawal in one. After this study, only case reports or smaller case series have been published describing HF in PAI, and congestive HF has not been a leading cause of death in epidemiological studies of PAI (9, 10) .
Isolated case reports have also described acute HF resulting from FC administration in patients with PAI, with clinical resolution after its withdrawal (66) (67) (68) . Six cases of PAI with coexisting dilated cardiomyopathy have been recently reported (69) . Four patients were able to tolerate a careful balance of FC and medical treatments for HF, one needed FC withdrawal, and one was only on GC replacement without FC before HF developed (69) .
No study has so far investigated how to manage MC replacement treatment in HF in patients with PAI. Therefore, in line with international guidelines for HF, angiotensin-converting enzyme inhibitors, angiotensin II antagonists, or beta-blockers should be used (70) . The use of MR antagonists and or discontinuation of FC should be decided on an individual basis. Careful hemodynamic monitoring is needed, because treatment of HF may interfere with the action of FC.
Conclusions
The impact of MC replacement in PAI has been systematically investigated in only a few studies with limited number of patients ( Table 1) . The current MC replacement in PAI may not be adequate in some patients because there are data suggesting that many patients with PAI are underreplaced and compensated for by overreplacement with GCs. Long-term outcome in PAI on conventional treatment have shown that morbidity remains high and life expectancy is reduced, mainly due to cardiovascular events. In addition, these patients still show a significantly compromised QoL despite their replacement therapy. Over the last two decades, various approaches have been undertaken to optimize GC treatment (e.g., reducing the overall daily cortisol exposure), trying to mimic the physiological diurnal variation in serum cortisol, whereas MC replacement has received little attention. More careful optimization of MC replacement therapy may be of importance in patients with PAI to restore QoL and improve their long-term outcome.
